Ebola outbreak in Guinea, 2021: Clinical care of patients with Ebola virus disease

Background: Experience from the Zaire Ebolavirus epidemic in the eastern Democratic Republic of the Congo (2018­2020) demonstrates that early initiation of essential critical care and administration of Zaire Ebolavirus specific monoclonal antibodies may be associated with improved outcomes among patients with Ebola virus disease (EVD). Objectives: This series describes 13 EVD patients and 276 patients with suspected EVD treated during a Zaire Ebolavirus outbreak in Guinea in 2021. Method: Patients with confirmed or suspected EVD were treated in two Ebola treatment centres (ETC) in the region of N'zérékoré. Data were reviewed from all patients with suspected or confirmed EVD hospitalised in these two ETCs during the outbreak (14 February 2021 ­ 19 June 2021). Ebola-specific monoclonal antibodies, were available 2 weeks after onset of the outbreak. Results: Nine of the 13 EVD patients (age range: 22­70 years) survived. The four EVD patients who died, including one pregnant woman, presented with multi-organ dysfunction and died within 48 h of admission. All eight patients who received Ebola-specific monoclonal antibodies survived. Four of the 13 EVD patients were health workers. Improvement of ETC design facilitated implementation of WHO-recommended 'optimized supportive care for EVD'. In this context, pragmatic clinical training was integrated in routine ETC activities. Initial clinical manifestations of 13 confirmed EVD patients were similar to those of 276 patients with suspected, but subsequently non confirmed EVD. These patients suffered from other acute infections (e.g. malaria in 183 of 276 patients; 66%). Five of the 276 patients with suspected EVD died. One of these five patients had Lassa virus disease and a coronavirus disease 2019 (COVID-19) co-infection. Conclusion: Multidisciplinary outbreak response teams can rapidly optimise ETC design. Trained clinical teams can provide WHO-recommended optimised supportive care, including safe administration of Ebola-specific monoclonal antibodies. Pragmatic training in essential critical care can be integrated in routine ETC activities. Contribution: This article describes clinical realities associated with implementation of WHO-recommended standards of 'optimized supportive care' and administration of Ebola virus specific treatments. In this context, the importance of essential design principles of ETCs is underlined, which allow continuous visual contact and verbal interaction of health workers and families with their patients. Elements that may contribute to further quality of care improvements for patients with confirmed or suspected EVD are discussed.

Factores pronósticos clínicos determinantes en la supervivencia de pacientes con el virus Ébola / Clinical prognostic factors determining the survival of patients with the Ebola virus

Introducción: La enfermedad por el virus del Ébola presenta una elevada letalidad, por lo cual resulta de gran interés la realización de investigaciones que aborden las manifestaciones clínicas que pudieran ser factores pronósticos de supervivencia. Objetivo: Evaluar factores pronósticos de los pacientes enfermos de ébola. Métodos: El universo lo constituyó la totalidad (n = 350) de pacientes ingresados. Se emplearon medidas de resumen para variables cualitativas, estimaciones puntuales y por intervalos para las cuantitativas, así como las pruebas de significación Kaplan-Meier, regresión de Cox y Odds Ratio. Se trabajó con un nivel de confiabilidad del 95 por ciento. Resultados: La supervivencia global fue del 42,5 por ciento. La media de supervivencia, de aproximadamente 10 días (IC: 9 - 11 días). Los pacientes que ingresaron en estado grave (OR = 3,76), que tuvieron dolor lumbar (OR = 2,24), que refirieron cefalea (OR = 2,22), que presentaron fiebre (OR=2,16), que aquejaron de dolor abdominal (OR=1,95) y a quienes se les constató inyección conjuntival (OR = 1,86), tuvieron mayor probabilidad de fallecer, que quienes ingresaron sin estos síntomas y signos. Conclusiones: La supervivencia fue elevada, pese a las complicaciones presentadas. Los síntomas y signos predictores de muerte en los pacientes fueron: la gravedad del paciente al momento del ingreso, la presencia de dolor lumbar, cefalea, fiebre, dolor abdominal e inyección conjuntival(AU)

Introduction: Ebola virus disease has a high lethality, which is why it is of great interest to carry out research that addresses clinical manifestations that could be prognostic factors for survival. Objective: To evaluate prognostic factors of Ebola patients. Methods: the universe was constituted by the totality (n = 350) of admitted patients. Summary measures were used for qualitative variables, point and interval estimates for quantitative variables, as well as Kaplan-Meier significance tests, Cox regression and Odds Ratio. We worked with a 95% level of reliability. Results: The overall survival was 42.5 por ciento. The average survival, approximately 10 days (CI: 9-11 days). Patients who were admitted in serious condition (OR = 3.76), who had low back pain (OR = 2.24), who reported headache (OR = 2.22), who presented fever (OR = 2.16), who they suffered from abdominal pain (OR = 1.95) and who were found to have conjunctival injection (OR = 1.86), were more likely to die than those who entered without these symptoms and signs. Conclusions: Survival was high, despite the complications presented. The symptoms and predictive signs of death in the patients were: the severity of the patient at admission, the presence of low back pain, headache, fever, abdominal pain and conjunctival injection(AU)

Data Fitting and Scenario Analysis of Vaccination in the 2014 Ebola Outbreak in Liberia

OBJECTIVES: This study aimed to extend an epidemiological model (SEIHFR) to analyze epidemic trends, and evaluate intervention efficacy. METHODS: SEIHFR was modified to examine disease transmission dynamics after vaccination for the Ebola outbreak. Using existing data from Liberia, sensitivity analysis of various epidemic scenarios was used to inform the model structure, estimate the basic reproduction number ℜ₀ and investigate how the vaccination could effectively change the course of the epidemic. RESULTS: If a randomized mass vaccination strategy was adopted, vaccines would be administered prophylactically or as early as possible (depending on the availability of vaccines). An effective vaccination rate threshold for Liberia was estimated as 48.74% among susceptible individuals. If a ring vaccination strategy was adopted to control the spread of the Ebola virus, vaccines would be given to reduce the transmission rate improving the tracing rate of the contact persons of an infected individual. CONCLUSION: The extended SEIHFR model predicted the total number of infected cases, number of deaths, number of recoveries, and duration of outbreaks among others with different levels of interventions such as vaccination rate. This model may be used to better understand the spread of Ebola and develop strategies that may achieve a disease-free state.

Purification and characterization of monoclonal IgG antibodies recognizing Ebola virus glycoprotein

PURPOSE: The goal of this study was to purify and characterize Ebola virus glycoprotein (GP)-specific IgG antibodies from hybridoma clones. MATERIALS AND METHODS: For hybridoma production, mice were injected by intramuscular-electroporation with GP DNA vaccines, and boosted with GP vaccines. The spleen cells were used for producing GP-specific hybridoma. Enzyme-linked immunosorbent assay, Western blot assay, flow cytometry, and virus-neutralizing assay were used to test the ability of monoclonal IgG antibodies to recognize GP and neutralize Ebola virus. RESULTS: Twelve hybridomas, the cell supernatants of which displayed GP-binding activity by enzyme-linked immunosorbent assay and the presence of both IgG heavy and light chains by Western blot assay, were chosen as a possible IgG producer. Among these, five clones (C36-1, D11-3, D12-1, D34-2, and E140-2) were identified to secrete monoclonal IgG antibodies. When the monoclonal IgG antibodies from the 5 clones were tested for their antigen specificity, they recognized GP in an antigen-specific and IgG dose-dependent manner. They remained reactive to GP at the lowest tested concentrations (1.953–7.8 ng/mL). In particular, IgG antibodies from clones D11-3, D12-1, and E140-2 recognized the native forms of GP expressed on the cell surface. These antibodies were identified as IgG1, IgG2a, or IgG2b kappa types and appeared to recognize the native forms of GP, but not the denatured forms of GP, as determined by Western blot assay. Despite their GP-binding activity, none of the IgG antibodies neutralized Ebola virus infection in vitro, suggesting that these antibodies are unable to neutralize Ebola virus infection. CONCLUSION: This study shows that the purified IgG antibodies from 5 clones (C36-1, D11-3, D12-1, D34-2, and E140-2) possess GP-binding activity but not Ebola virus-neutralizing activity.

Enfermedad por el virus Ébola medidas de bioseguridad / Ebola virus disease biosafety measures

Resumen El virus Ébola representa el patógeno prototipo de fiebre hemorrágica viral, causando una enfermedad severa de alta tasa de mortalidad. Esta alta mortalidad, combinada con la ausencia de vacunación y de un tratamiento específico, hace que el virus Ébola sea un patógeno importante para la salud pública. La fiebre hemorrágica de Ébola se cree es una zoonosis con persistencia del virus en especies de reservorios encontrados en áreas endémicas. A pesar de todos los esfuerzos realizados en cada brote para identificar los reservorios naturales no se conocen huéspedes potenciales ni los artrópodos vectores. El manejo de los casos está basado en el aislamiento de los pacientes y en el uso de barreras de aislamiento, tales como ropa e implementos de protección como respiradores. Debido a su rápida propagación la OMS declaró que la enfermedad por el virus Ébola representa una emergencia de salud pública más allá de las fronteras y exhortó a la comunidad internacional a tomar las acciones necesarias para detener la epidemia.

Abstract Ebola virus is regarded as the prototype pathogen of viral hemorrhagic fever, causing severe disease and high case fatality rates. This high fatality, combined with the absence ot treatment and vaccination options, makes Ebola virus an important public health pathogen. Ebola hemorrhagic fever is thought to be a classic zoonosis with persistence of the Ebola virus in a reservoir species generally found in endemic areas. Although much effort has been made to identify the natural reservoirs with every large outbreak of Ebola hemorrhagic fever, neither potential hosts norarthropod vectors have been identified. Case management is based on isolation of patients and use of strict barrier nursing procedures, such as protective clothing and respirators. In addition, its rapid propagation has led the Word Health Organization (WHO) to declare on August 2014 that Ebola virus disease represents a public health emergency of international concern and urged the international community to take action to stop its spread.

Ebola virus – from neglected threat to global emergency state / Vírus ébola – de ameaça negligenciada ao estado de emergência global

SUMMARY Objective: This review aims to update knowledge about Ebola virus disease (EVD) and recent advances in its diagnosis, treatment and prevention. Method: A literature review was performed using the following databases: ISI Web of Knowledge, PubMed, IRIS, Scopus and the websites of the CDC and the WHO. Additionally, we have included articles and reports referenced in the basic literature search, and news that were considered relevant. Results: The Ebola virus, endemic in some parts of Africa, is responsible for a severe form of hemorrhagic fever in humans; bats are probably its natural reservoir. It is an extremely virulent virus and easily transmitted by bodily fluids. EVD's complex pathophysiology, characterized by immunosuppression as well as stimulation of an intense inflammatory response, results in a syndrome similar to septic shock. The diagnosis is difficult due to the initial symptoms that mimic other diseases. Despite the high mortality rates that can amount to 90%, a prophylaxis (chemical or vaccine) or effective treatment does not exist. Two vaccines and experimental therapies are being developed for the prevention and treatment of EVD. Conclusion: Although the virus is known for about 40 years, the lack of knowledge obtained and the disinterest of government authorities in the countries involved justify the state of emergency currently exists regarding this infectious agent. Only the coordination of multiple entities and the effective commitment of the international community will facilitate the control and effective prevention of EVD.

RESUMO Objetivo: esta revisão tem como objetivo atualizar os conhecimentos sobre a doença do vírus ébola (DVE) e sobre os recentes avanços nos métodos de diagnóstico, tratamento e prevenção. Método: foi realizada uma revisão de literatura, utilizando as seguintes bases de dados: ISI Web of Knowledge, PubMed, IRIS, Scopus e os sites do Centers for Disease Control and Prevention (CDC) e da Organização Mundial da Saúde (OMS). Adicionalmente, foram incluídos artigos e relatórios referenciados na pesquisa bibliográfica de base e notícias consideradas relevantes. Resultados: o vírus ébola, endêmico de algumas regiões da África, é responsável por uma forma grave de febre hemorrágica no homem, e os morcegos são provavelmente o seu reservatório natural. É um vírus extremamente virulento e de fácil transmissão pelos fluidos corporais. A complexa fisiopatologia da doença, caracterizada pela imunossupressão e pelo estímulo a uma intensa resposta inflamatória, resulta em uma síndrome semelhante ao choque séptico. O seu diagnóstico é difícil, por causa da sintomatologia inicial, que mimetiza outras doenças. Apesar das altas taxas de mortalidade, que podem alcançar os 90%, não existe profilaxia (química ou vacinal) ou tratamento eficaz. Encontram-se em desenvolvimento duas vacinas e terapias experimentais para a prevenção e o tratamento da DVE. Conclusão: apesar de ser um vírus conhecido há cerca de 40 anos, o escasso conhecimento obtido e o desinteresse das entidades governamentais de países envolvidos justificam o estado de emergência que se vive atualmente em relação a esse agente infeccioso. A coordenação por múltiplas entidades e o empenho efetivo da comunidade internacional facilitarão o seu controle e a prevenção eficaz.

Ébola: ¿Enfermedad viral o patología social? / Ebola: Viral disease or social pathology?

El Ébola es una enfermedad infecciosa viral altamente letal que puede ser producida por una de sus varias cepas, el 8 de agosto del 2014 la Organización Mundial de la Salud la declaró como una "emergencia de salud pública de interés internacional" debido al brote de la cepa Zaire que ha afectado a varios países de África occidental Guinea Conakry, Liberia, Sierra Leona, Malí y Nigeria, y que deja a enero de 2015 un saldo de más de 20.000 personas infectadas y al menos 8000 muertes. El presente artículo reflexiona sobre la situación actual de la epidemia, sus consecuencias particulares sobre el personal de atención en salud y su relación con los determinantes en salud de dichas poblaciones.

Ebola is an infectious disease highly lethal caused by one of the Ebola virus strains, this year on August 8th, the World Health Organization declared the Ebola outbreak a 'public health emergency of international concern' because the outbreak of Zaire strain who affected several countries in western Africa -Guinea Conakry, Liberia, Sierra Leone, Nigeria ­ and have already infected more than 20000 people and killed at least 8000. This paper reflects on the epidemic current context, their specific consequences over the health staff and the relationship between the determinants of health of such communities.

Ébolavirus: biología molecular y evasión de la respuesta inmune / Ebolavirus: molecular biology and immune response evasion

La actual epidemia de enfermedad por virus Ébola que azota al África Occidental ha cobrado la vida de alrededor de 9 000 personas con más de 22 000 infectados en seis países, y algunos casos aislados han llegado a ciudades de Europa y Estados Unidos. Aunque el curso clínico de la enfermedad es bien conocido, los mecanismos específicos que explican su patogenicidad no han sido completamente delineados. Los casos fatales de infección por Ébolavirus están marcados por un fallo catastrófico de las respuestas inmune innata y adaptativa, mediado por proteínas codificadas por el virus, así como por propiedades asociadas a su estructura. El genoma del Ébolavirus está constituido solamente por siete genes que codifican unas 10 proteínas, suficientes para desencadenar una enfermedad cuya letalidad varía del 40 al 90 por ciento. En el centro de la desregulación inducida por el Ébola se encuentra una temprana y coordinada actuación de las proteínas VP24, VP30 y VP35, que conduce a niveles elevados de replicación viral, a una inapropiada temporización de la cascada de liberación de linfocinas y a la muerte, tanto de células presentadoras de antígenos, como de células efectoras. Los complejos mecanismos del Ébola para regular selectivamente la respuesta inmune y su patogenicidad variable en diferentes especies hospederas, convierten a este virus en un adversario formidable, así como de un notable interés científico(AU)

The current Ebolavirus disease outbreak that strikes West Africa has claimed the life of around 9 000 people and has infected more than 22 000 in six countries, and some isolated cases have reached cities of Europe and the United States. Though the clinical course of the disease is well known, the specific mechanisms of its pathogenicity have not been fully delineated yet. Fatal cases of Ebolavirus disease are marked by a catastrophic failure of both innate and adaptive immune responses, mediated by virus-encoded proteins as well as properties associated with its structure. Ebolavirus genome comprises only seven genes encoding about 10 proteins, enough to cause a disease which fatality fluctuates from 40 to 90 percent. At the heart of Ebola-induced immune dysregulation is an early and coordinated disruption by VP24, VP30, and VP35 that leads to elevated levels of virus replication, a cascade of inappropriately timed cytokine release, and death of both antigen-presenting and responding immune cells. The complex mechanisms of Ebola to selectively regulate immune responses and its variable pathogenicity in different host species makes this virus both, a challenging foe and scientifically interesting(AU)

Enfermedad por el virus Ébola medidas de bioseguridad / Ebola virus disease biosecurity measures

El virus Ébola representa el patógeno prototipo de fiebre hemorrágica viral, causando una enfermedad severa de alta tasa de mortalidad. Esta alta mortalidad, combinada con la ausencia de vacunación y de un tratamiento específico, hace que el virus Ébola sea un patógeno importante para la salud pública. La fiebre hemorrágica de Ébola se cree es una zoonosis con persistencia del virus en especies de reservorios encontrados en áreas endémicas. A pesar de todos los esfuerzos realizados en cada brote para identificar los reservorios naturales no se conocen los huéspedes potenciales ni los artrópodos vectores. El manejo de los casos está basado en el aislamiento de los pacientes y en el uso de barreras de aislamiento, tales como ropa e implementos de protección como respiradores. Debido a su rápida propagación la OMS declaró que la enfermedad por el virus Ébola representa una emergencia de salud pública más allá de las fronteras y exhortó a la comunidad internacional a tomar las acciones necesarias para detener la epidemia.

Ebola virus is regarded as the prototype pathogen of viral hemorrhagic fever, causing severe disease and high case-fatality rates. This high fatality, combined with the absence of treatment and vaccination options, makes Ebola virus an important public health pathogen. Ebola hemorrhagic fever is thought to be a classic zoonosis with persistence of the Ebola virus in a reservoir species generally found in endemic areas. Although much effort has been made to identify the natural reservoirs with every large outbreak of Ebola hemorrhagic fever, neither potential hosts nor arthropod vectors have been identified. Case management is based on isolation of patients and use of strict barrier nursing procedures, such as protective clothing and respirators. In addition, its rapid propagation has led the World Health Organization (WHO) to declare on August 2014 that Ebola virus disease represent a public health emergency of international concern and urged the international community to take action to stop the spread.

O risco da contaminação global: o combate à epidemia de Ebola na África como vetor de cooperação internacional / The global contamination risk: the battle against Ebola epidemic in Africa as a vector of international cooperation / /El riesgo de contaminación global: la lucha contra la epidemia por el virus del Ebola en África como un vector de la cooperación internacional

Considerada a maior epidemia de Ebola desde o primeiro surto em 1976, o oeste africano tem enfrentado grandes desafios, sobretudo endógenos, para conter a disseminação da doença. Objetiva-se analisar a atual epidemia de Ebola à luz do neoinstitucionalismo liberal e da lógica da ação coletiva, utilizando como metodologia a estratégia de nested analisys. Conclui-se que o risco de uma pandemia de Ebola tem funcionado como incentivo para que os atores envolvidos cooperem. Os resultados deslocam a discussão para uma área pouco explorada academicamente: a ética médica no âmbito das relações internacionais, que suscita indagações, tais como “por que africanos não têm prioridade no tratamento diferenciado contra o Ebola?” e “qual o verdadeiro papel da OMS ao lidar com grandes epidemias?”. O presente trabalho inova ao tratar lógicas por trás da cooperação internacional em matéria de saúde no continente africano e por agregar a infografia cartográfica à literatura sobre política internacional...

Considered the largest epidemic of Ebola since the first outbreak in 1976, West Africa has faced great challenges, especially endogenous, to contain the disease spreading. Our objective is to analyze the current epidemic of Ebola in the light of the neoliberal institutionalism and the logic of collective action, using as methodology the strategy of nested analysis. It is concluded that the risk of an Ebola pandemic has worked as an incentive for the involved actors want to cooperate. The results lead the discussion to an area little explored academically: the international medical ethics, which raises questions like: “why is not given priority to Africans in the differential treatment against Ebola?” and “what is the true role played by WHO when dealing with large epidemics?” The study breaks new ground when it deals with the logic behind the international cooperation concerning health in Africa and adds infographic maps to international politics literature...

Considerada la mayor epidemia por el virus del Ébola desde el primer brote en 1976, África Occidental ha enfrentado a grandes desafíos, en especial endógenos, para contener la propagación de la enfermedad. Este trabajo tiene como objetivo analizar la actual epidemia por el virus del Ébola de acuerdo con el neoinstitucionalismo liberal y la lógica de la acción colectiva, utilizando como metodología la estrategia de“nested analysis”. Se concluye que el riesgo de una pandemia por el virus del Ébola ha funcionado como un incentivo para que los actores interesados quieran cooperar. Los resultados llevan la discusión a una área poco trabajada en la academia: la ética médica en las relaciones internacionales, que suscita preguntas como: “¿por qué los africanos no tienen prioridad en el tratamiento diferenciado contra el virus del Ébola?”y “¿cuál es el verdadero papel de la OMS cuando trabaja contra grandes epidemias?”. El estudio abre nuevos caminos al tratar de la lógica detrás de la cooperación internacional en materia de salud en África y al agregar mapas infográficos a la literatura política internacional...

Ebola outbreak in Western Africa 2014: what is going on with Ebola virus?

The 2014 outbreak of Ebola virus disease (EVD) in West Africa, caused by Ebola virus (Zaire Ebola virus species), is the largest outbreak of EVD in history. It cause hemorrhagic fever in human and nonhuman primates with high mortality rate up to 90% and can be transmitted by direct contact with blood, body fluids, skin of EVD patients or persons who have died of EVD. As of December 17, 2014, 450 healthcare personnel are known to have been infected with Ebola, of whom 244 died. For development of Ebola vaccine and treatment are highly difficult due to its dangerous and accessibility that requires biosafety level 4 (BSL-4) to conduct experiment. Also there is no specific vaccine and treatment for Ebola virus; however, many candidate vaccines and antiviral-drugs such as ZMapp and TKM-Ebola are being developed for Ebola virus disease. In this review, we focus on the epidemiology of 2014 outbreak of Ebola virus and candidate agent for preventing and curing from Ebola virus.

Laboratory diagnostic methods of Ebola virus diseases / 中华检验医学杂志

Etiological and serological testing, including virus genome, virus antigen, anti-virus antibodies, virus culture and identification, were the standard laboratory tests to confirm or exclude Ebola virus infections.Moreover, other laboratory tests, such as blood routine tests, liver and kidney function tests, serum electrolyte tests, and coagulation function tests, were very important to the clinical diagnosis and treatment of Ebola virus disease ( EVD) patients.Based on working experiences and practices in the China Ebola Treatment Center and available publications, opinions about the detailed clinical significance and associated key point of biosafty prevention and protection protocols of above described laboratory tests for the clinical diagnosis and treatment of EVD were provided.

Bibliometric analysis on research of Ebola virus and Ebola virus disease / 中华传染病杂志

Objective To get a knowledge of the current status of international research on Ebola virus and Ebola virus disease (EVD).Methods All the articles about EVD from PubMed database were retrieved and analyzed.After core subject headings had been identified by BICOMB,the co-occurrence matrix was established.Cluster analysis about co-occurrence matrix was performed by SPSS 19.0.The visualized network image was drawn by Ucinet 6.0.Results A total of 1 384 literatures were involved in the analysis,with the earliest one published in 1979.The number of literatures was increasing along with time and disease outbreaks.Totally 1 213 (87.6％) literatures were published by Europe and U.S.There were 27 core subjects and they were clustered into 3 research areas from 1979 to 2014,including Ebola virus genome structure and viral proteins,especially the envelope protein; immunology of Ebola virus and animal models; epidemiology,diagnosis and treatment of Ebola hemorrhagic fever.The visualized social network reflected that the prevention of EVD,the genome and immunology of Ebola were the major concerns.Conclusion It has been 35 years since the literatures on Ebola virus and EVD emerged.The United States and the United Kingdom are the top two countries in this field.The present studies have laid a crucial foundations for developing effective vaccines and diagnostic reagents.

Five cases report of Ebola virus disease / 中华传染病杂志

Objective To analyze the clinical characteristics ,treatment and outcome of Ebola virus disease so as to provide early clinical recognition and treatment for this disease .Methods The clinical manifestations and treatment of 5 cases of Ebola virus disease in Ebola Holding Center of Sierra‐Leone China Friendship Hospital from 15 March 2015 to 15 May 2015 were retrospectively analyzed .And the clinical characteristics and possible effective treatment were discussed combined with related literature . Results Five patients were diagnosed with Ebola virus disease by polymerase chain reaction and 4 cases of 5 patients had confirmed contact history ,while 1 case had no clear contact history .All the 5 cases presented with low fever ,headache and joint pain .Three cases then progressed into severe gastrointestinal symptoms such as nausea ,vomiting ,diarrhea and hypovolemic shock .The patients presented with fast heart rate and shortness of breath and other inflammatory response syndrome in acute phase .One patient rapidly progressed to liver pain ,jaundice and anuria ,then died .Three severe cases recovered after treated with fluid resuscitation ,circulation maintenance and electrolyte balance in acute phase .Conclusions The early symptoms of Ebola virus disease are low fever ,joint pain and nausea .Frequent vomiting ,diarrhea , low blood pressure and electrolyte disorder indicate severe conditions .Shock and electrolyte disorder are deadly complications .Early recognition ,diagnosis and treatment are the key to improve the prognosis .

Situación del brote de Ébola en África Occidental en el año 2014 / Status Ebola outbreak in West Africa in 2014

Resumen Desde el comienzo del brote en diciembre del 2013, y hasta el corte del 20 de septiembre de 2014, de un total de 6,185 casos probables de Ébola, se han registrado un total de 2,909 defunciones. Con una letalidad inferior al 50%, considerablemente menor a la reportada en brotes previos de la enfermedad, se cree que dichas estimaciones están sesgadas debido a la dificultad en la recolección y análisis de la información. El 23 de septiembre, la OMS presentó una revisión a dichas estimaciones, señalando una letalidad del 70%. El brote se registró originalmente en Liberia y Guinea, y posteriormente se han repostado casos en Nigeria, Sierra Leona y Senegal. Todos los casos confirmados por laboratorio han sido positivos al vírus del Ébola. La fuente inicial del brote se localizó en la aldea de Meliandou, prefectura de Guáckádou, Guinea. El caso índice fue un niño de 2 años, el cual falleció el 6 de diciembre de 2013. Su madre, hermana y abuela también fallecieron también por la enfermedad. La gente de la aldea infectada por estas víctimas iniciales transmitió el brote a aldeas aledañas. El brote se esparció inicialmente a Liberia y posteriormente a Sierra Leona. En los tres países continúa la circulación del virus. La llegada de algunos casos a Nigeria y Senegal obligó a dichos países a cerrar sus fronteras, y a poner en cuarentena a ciudadanos de los que se sospechara que estuvieran infectados. Hasta la fecha, ambos países no han presentado casos nuevos, por lo que se consideran en control. Asimismo, se han reportado casos importados de dichos países en Estados Unidos, Francia, Alemania, España, Suiza y el Reino Unido.

Abstract Since the onset of the outbreak im December 2013 and up to the September 20 cut-off, there have been 2,909 deaths in the 6,185 likely cases of Ebola. It is considered that the letality under 50%, considerably lower tan the one reported in previous outbreaks of the disease, is biased due to the dificulty to collect and analyze information. On September 23, WHO showed a review of such estimations, indicating 70% letality. The outbreak was originally reported in Liberia and Guinea. Further cases were reported in Nigeria, Sierra Leone, and Senegal. All the cases confirmed by laboratory have been EBOV positive. The initial source of the outbreak was found in the village called Meliandou in the in Guéckédou Prefecture, Guinea. The index case was a two-year-old boy, who die don December 6, 2013. His mother, sister and grandmother also died because of the disease. The people from this village transmitted the disease to people in nera-by villages. The outbreak initially spread to Liberia and then to Sierra Leone. Virus circulation continues in three countries. The transmision of some cases to Nigeria and Senegal led these countries to close their borders to the three formerly mentioned countries and quarantine suspicious individuals. So far, neither country has presented new cases; hence they are considered under control. Likewise, cases imported from those countries into the United States, France, Germany, spain, Switzerland, and the Uited Kingdom have been reported.

Ébola: Epidemia en el Siglo XXI / Ebola: Epidemic in the twenty-first Century

La fiebre hemorrágica por virus Ébola, que pertenece a la familia de Filovirus, afecta tanto a animales como a humanos, estos ultimos llegan a ser huéspedes accidentales de dicho virus. Existen actualmente 4 especies de la familia Filoviridae, del cual el más mortal para la especie humana es el Zaire Ébola virus. La transmisión se da por contacto directo con tejido animal o humano infectado, a si mismo por el consumo de los mismos. El cuadro clínico se manifiesta después de un corto periodo de incubación (2-21 días), cursando con fiebre, malestar general, cefaleas, vómitos, diarreas y hemorragias generalizadas. Actualmente está en investigación el tratamiento mostrando resultados alentadores.

Ebola hemorrhagic fever virus, which belongs to the Filovirus famiia affects both animals and humans, this last become accidental hosts of the virus. There are currently 4 Filoviridae species of the family, of which the most deadly for the human species is the Zaire Ebola virus. Transmission occurs by direct contact with infected animal or human tissue itself by eating them. The symptoms appear after a short incubation period (2-21 days), studying with fever, malaise, headache, vomiting and diarrhea and bleeding generalized.